Acute Porphyria Drug Database

Monograph

A10AE56 - Insulin Degludec and Liraglutide
Propably not porphyrinogenic
PNP

Rationale
Combination of two substances classified as NP (insulin degludec) and PNP (liraglutide). For more extensive monographs, please search the individual substances insulin degludec (ATC A10AE06) and liraglutide (A10BX07).
Chemical description
Liraglutide is a human glucagon-like peptide-1 analog, with a 97 per cent sequence homology to the human hormone. Insulin degludec is an antidiabetic pancreatic hormone consisting of two polypeptide chains, A and B, connected by two diulphide bridges.

Similar drugs
Explore alternative drugs in similar therapeutic classes A10A / A10AE or go back.

Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.
Netherlands
Xultophy · Xultophy 100 eenheden/ml + 3,6 mg/ml oplossing voor injectie
Belgium
Xultophy · Xultophy 100 U/ml - 3.6 mg/ml sol. inj. s.c. stylo prérempli
United Kingdom
Xultophy · Xultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pens
Denmark
Xultophy
Norway
Xultophy
Poland
Xultophy
Luxembourg
Xultophy
Iceland
Xultophy
Finland
Xultophy
Latvia
Xultophy
Serbia
Xultophy · Xultophy®
 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙